GLP1R and metabolic dysfunction-associated steatotic liver disease: One of the most promising classes of drugs for pediatric MASLD is glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have shown significant efficacy in treating obesity and related metabolic disorders.